Filing summary: Oculus Innovative Sciences, Inc. Form 10-Q
Entity and period: The filing identifies the registrant as Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc. It reports the quarter and six months ended September 30, 2012; the company’s fiscal year ends March 31. Unless noted otherwise, amounts below are in millions of U.S. dollars.
Business context
Oculus develops and sells healthcare products based primarily on its Microcyn technology, alongside nutritional products and contract laboratory testing. Its markets include wound care, dermatology, surgical care and animal healthcare. The filing says the company lacked U.S. regulatory approval to market Microcyn as a drug or medical device with an antimicrobial or wound-healing indication.
Financial performance
| Metric | Three months ended September 30, 2012 | Prior-year quarter | Six months ended September 30, 2012 | Prior-year six months |
|---|---|---|---|---|
| Total revenue | $4.526 | $3.663 | $8.577 | $6.603 |
| Gross profit | $3.200 | $2.778 | $6.084 | $4.727 |
| Operating loss | $(0.817) | $(0.630) | $(1.312) | $(2.648) |
| Net loss | $(1.519) | $(0.839) | $(1.074) | $(3.014) |
| Net loss per share | $(0.05) | $(0.03) | $(0.07) | $(0.11) |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $3.292 | $(1.468) |
- Quarterly revenue rose 24%; six-month revenue rose 30%. Product revenue growth in the U.S. and Mexico more than offset declines in Europe and other regions. Service revenue was broadly flat.
- Gross margin on total revenue was about 71% for both the quarter and six-month period, versus about 76% and 72%, respectively, a year earlier. Management attributed lower product margins to product mix and the More Pharma arrangement; product gross margin was 74% for the six-month period versus 76% in the prior year.
- Quarterly net loss widened by $0.680 million, despite higher revenue, reflecting higher operating expenses and a $0.397 million non-cash derivative revaluation loss. Six-month net loss narrowed, helped by an $0.850 million non-cash derivative revaluation gain. The six-month loss available to common shareholders was $2.136 million after a $1.062 million deemed preferred dividend.
- At September 30, cash and equivalents were $8.310 million, working capital was $4.996 million, and total assets were $13.392 million. Current liabilities were $7.451 million. Debt, net of discounts, was $2.569 million, including $1.477 million current and $1.092 million long-term. Stockholders’ deficiency was $0.501 million.
- Six-month operating cash flow of $3.292 million was primarily driven by the $5.1 million More Pharma upfront payment and a $4.408 million increase in accrued expenses and other liabilities; it should not be read as recurring operating cash generation. Investing cash use was $0.205 million and financing cash provided was $1.874 million. Cash increased from $3.351 million at March 31.
Material changes, outlook and risks
- More Pharma agreements: Oculus agreed to exclusive licensing, distribution and supply arrangements covering Mexico and additional territories for upfront payments totaling $5.1 million. The company is recognizing that amount over an estimated three to five years; $0.183 million was recognized in the quarter. Product sales to More Pharma are recognized on a sell-through basis. The transition of Mexico sales operations also generated about $0.410 million of one-time severance and related costs.
- Financing and liquidity: An April 2012 securities offering generated $2.832 million net proceeds; the preferred shares were converted into 1,111,111 common shares. Management said cash was expected to fund working capital and sales, marketing and R&D through at least October 1, 2013, but the company expected continuing losses and might need more capital. No new financing was committed, and management warned that inability to raise funds could require R&D cuts. U.S. pivotal trials were to be delayed pending a strategic funding partner or additional capital.
- Management outlook: R&D expense was expected to increase slightly over coming quarters; SG&A was expected to decline as Mexico-related sales costs fell. No quantified revenue or earnings guidance was provided.
- Regulatory and commercial exposure: A strategic partner received an FDA warning letter in July 2012 concerning manufacturing and marketing of certain Microcyn-based products. Oculus was assessing potential effects; the filing notes the partner could stop sales and that the FDA could require other actions, including a recall. The company also disclosed a prior voluntary Class II labeling recall, described as having nominal costs and no material revenue impact.
- Listing and legal matters: Nasdaq had notified the company of failures to meet the $35 million market-value requirement and the $1 minimum bid-price requirement, with stated cure deadlines of November 19 and December 17, 2012, respectively. A lawsuit in Mexico alleging, among other claims, conversion, tortious interference and defamation was being contested; no loss reserve was accrued.
- Subsequent events: In November 2012, Oculus issued 4,320,985 restricted shares, valued at $3.5 million, to Venture Lending & Leasing entities in exchange for surrender of warrants with put-option cash values totaling $2.0 million. The filing also reports a warrant amendment extending expiration to 2016 in exchange for waiver of certain cash-settlement features.
Most important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Oculus Innovative Sciences, not Sonoma Pharmaceuticals.
- Assess whether the reported cash runway depended on the one-time More Pharma proceeds, and whether additional financing was obtained after the filing.
- Verify More Pharma’s minimum-purchase performance, product sell-through, and the timing and basis for recognizing the $5.1 million upfront fees.
- Check the outcome of the Nasdaq listing deficiencies and the subsequent share issuance and warrant amendments, including their dilution and debt effects.
- Review developments in the partner’s FDA warning-letter response, U.S. regulatory approvals and trial funding, and the Mexico litigation.